Accéder au contenu
Merck
Toutes les photos(1)

Documents

S1764

Sigma-Aldrich

Complement sera human

lyophilized powder

Synonyme(s) :

Human Serum Complement

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Numéro MDL:
Code UNSPSC :
12352202
Nomenclature NACRES :
NA.61

Source biologique

human

Niveau de qualité

Forme

lyophilized powder

Origine

USA origin

Technique(s)

cell culture | mammalian: suitable

Impuretés

virus, tested

Conditions d'expédition

dry ice

Température de stockage

−20°C

Description générale

Complement serum is prepared from pooled human plasma and lyophilized from the amount of serum indicated on the label.

Application

Complement sera human has been used:
  • to incubate DLD-1 or SW-620 cells to quantify C5a release
  • in multiplex bead antibody-binding assay to assay C3d
  • in complement-dependent cytotoxicity assay

Complement sera human has been used:
  • to incubate DLD-1 or SW-620 cells to quantify C5a release
  • in multiplex bead antibody-binding assay to assay C3d
  • in complement-dependent cytotoxicity assay

The activity of complement sera can be determined by hemolytic assays in vitro.

Forme physique

Lyophilized powder from indicated amount of serum

Remarque sur l'analyse

Hemolytic titer (CH50 units per ml) is determined by method of Kabat and Mayer. Actual titer given on label.

Clause de non-responsabilité

Ce produit, destiné à la recherche scientifique, est soumis à une réglementation spécifique en France, y compris pour les activités d′importation et d′exportation (Article L 1211-1 alinéa 2 du Code de la Santé Publique). L′acheteur (c′est-à-dire l′utilisateur FINAL) est tenu d′obtenir une autorisation d′importation auprès du ministère français de la recherche, mentionné à l′article L1245-5-1 II du Code de la Santé Publique. En commandant ce produit, vous confirmez détenir l′autorisation d′importation requise.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Chiaki Kawabata et al.
Biological & pharmaceutical bulletin, 44(2), 219-224 (2021-02-02)
Baculovirus vectors (BVs) are safely able to transduce foreign genes and express them in mammalian cells. However, the transduction activity of BVs is strongly reduced by the attack of serum complement, which is one of the major obstacles in the
Yui Suzuki et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(14), 4388-4399 (2019-04-26)
The anti-CCR4 mAb, mogamulizumab, offers therapeutic benefit to patients with adult T-cell leukemia-lymphoma (ATL), but skin-related adverse events (AE) such as erythema multiforme occur frequently. The purpose of this study was to determine the mechanisms by which mogamulizumab causes skin-related
Lisa Tomasi et al.
Open forum infectious diseases, 9(11), ofac554-ofac554 (2022-12-06)
The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect
Helen Kotanides et al.
Cancer immunology research, 8(10), 1300-1310 (2020-09-03)
The programmed cell death protein 1 receptor (PD-1) and programmed death ligand 1 (PD-L1) coinhibitory pathway suppresses T-cell-mediated immunity. We hypothesized that cotargeting of PD-1 and PD-L1 with a bispecific antibody molecule could provide an alternative therapeutic approach, with enhanced
S Nowicki et al.
Infection and immunity, 63(12), 4790-4794 (1995-12-01)
Human C1q displayed a dose-dependent protection of gonococcal cells (GC) from the bactericidal effect of newborn rat serum. All rat pups injected with C1q-preincubated GC developed bacteremia, while none of the animals injected with GC only were infected. After clearance

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique